ArticleDisease markers2022
Study of tRNA-Derived Fragment tRF-20-S998LO9D in Pan-Cancer.
Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- tRNA-derived fragments: mechanism of gene regulation and clinical application in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Pooled it
- Identification of a novel tRNA-derived small RNA fragment, tRF-16-2YU04DE, with the potential of inhibiting endometrial cancer progression.Medical oncology (Northwood, London, England) · 2025Article
- Research progress on the tsRNA biogenesis, function, and application in lung cancer.Non-coding RNA research · 2025Review
- Emerging roles and therapeutic potential of tRNA-Derived small RNAs in reproductive system diseases: a review.Frontiers in cell and developmental biology · 2025Review
- Transfer RNA‑derived small RNAs: A class of potential biomarkers in multiple cancers (Review).Oncology letters · 2024Review
- Emerging roles of tRNA-derived small RNAs in cancer biology.Experimental & molecular medicine · 2023Review
- An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology.British journal of cancer · 2023Review
- Characterization of tRNA-Derived Fragments in Lung Squamous Cell Carcinoma with Respect to Tobacco Smoke.International journal of molecular sciences · 2023Article
- Emerging roles of tRNA-derived fragments in cancer.Molecular cancer · 2023Review
- tRNA derived small RNAs-Small players with big roles.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose is to study the effect of tRNA-derived fragments (tRFs) on pan-cancer through bioinformatics. Methods: The expression information of tRF-20-S998LO9D, a type of tRF-5, was retrieved through MINTbase in pan-cancer and verified by qPCR. We preliminarily explored the effect of tRF-20-S998LO9D on cell proliferation in breast cancer and lung cancer cell lines. Then an online KM-plotter provided by OncotRF was used to discover the prognostic significance. GO/KEGG analyses were executed to predict the potential mechanism of tRF-20-S998LO9D in cancer. Results: We found that tRF-20-S998LO9D was highly expressed in a variety of cancers like breast invasive carcinoma, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung squamous cell carcinoma, pheochromocytoma and paraganglioma, and uterine corpus endometrial carcinoma. Inhibition of tRF-20-S998LO9D led to reduced cell proliferation in breast cancer (MCF-7) and lung squamous cell carcinoma (SK-MES-1) cells. Elevated tRF-20-S998LO9D indicated poor prognosis in a variety of cancers. tRF-20-S998LO9D might be involved in multiple cancer-related pathways. Conclusion: We concluded that tRF-20-S998LO9D was upregulated and negatively correlated with prognosis of a variety of cancers. It may be a potential cancer-promoting marker in pan-cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.